scholarly journals Leishmania Immunity: Advancing Immunotherapy and Vaccine Development

2020 ◽  
Vol 8 (8) ◽  
pp. 1201 ◽  
Author(s):  
Nnamdi M. Ikeogu ◽  
Gloria N. Akaluka ◽  
Chidalu A. Edechi ◽  
Enitan S. Salako ◽  
Chukwunonso Onyilagha ◽  
...  
Keyword(s):  
Vaccine Development ◽  
Treatment Options ◽  
Protozoan Parasite ◽  
Current Treatment ◽  
World Health ◽  
Parasitic Diseases ◽  
High Morbidity ◽  
The World ◽  
Protozoan Infections ◽  
Health Organization

Parasitic diseases still constitute a major global health problem affecting billions of people around the world. These diseases are capable of becoming chronic and result in high morbidity and mortality. Worldwide, millions of people die each year from parasitic diseases, with the bulk of those deaths resulting from parasitic protozoan infections. Leishmaniasis, which is a disease caused by over 20 species of the protozoan parasite belonging to the genus Leishmania, is an important neglected disease. According to the World Health Organization (WHO), an estimated 12 million people are currently infected in about 98 countries and about 2 million new cases occur yearly, resulting in about 50,000 deaths each year. Current treatment methods for leishmaniasis are not very effective and often have significant side effects. In this review, we discussed host immunity to leishmaniasis, various treatment options currently being utilized, and the progress of both immunotherapy and vaccine development strategies used so far in leishmaniasis. We concluded with insights into what the future holds toward the fight against this debilitating parasitic disease.

scholarly journals Nanotechnology Integration for SARS-CoV-2 Diagnosis and Treatment: An Approach to Preventing Pandemic

Nanomaterials ◽  
2021 ◽  
Vol 11 (7) ◽  
pp. 1841
Author(s):  
Syed Mohammed Basheeruddin Asdaq ◽  
Abu Md Ashif Ikbal ◽  
Ram Kumar Sahu ◽  
Bedanta Bhattacharjee ◽  
Tirna Paul ◽  
...  
Keyword(s):  
Treatment Options ◽  
Basic Structure ◽  
Current Treatment ◽  
World Health ◽  
Significant Progress ◽  
Immune Modulators ◽  
The World ◽  
Health Organization ◽  
Antiviral Medications ◽  
Nucleoside Inhibitors

The SARS-CoV-2 outbreak is the COVID-19 disease, which has caused massive health devastation, prompting the World Health Organization to declare a worldwide health emergency. The corona virus infected millions of people worldwide, and many died as a result of a lack of particular medications. The current emergency necessitates extensive therapy in order to stop the spread of the coronavirus. There are various vaccinations available, but no validated COVID-19 treatments. Since its outbreak, many therapeutics have been tested, including the use of repurposed medications, nucleoside inhibitors, protease inhibitors, broad spectrum antivirals, convalescence plasma therapies, immune-modulators, and monoclonal antibodies. However, these approaches have not yielded any outcomes and are mostly used to alleviate symptoms associated with potentially fatal adverse drug reactions. Nanoparticles, on the other hand, may prove to be an effective treatment for COVID-19. They can be designed to boost the efficacy of currently available antiviral medications or to trigger a rapid immune response against COVID-19. In the last decade, there has been significant progress in nanotechnology. This review focuses on the virus’s basic structure, pathogenesis, and current treatment options for COVID-19. This study addresses nanotechnology and its applications in diagnosis, prevention, treatment, and targeted vaccine delivery, laying the groundwork for a successful pandemic fight.

Treatment Options in COVID-19: The Role of Bioavailable Antiviral Ribonucleoside Analog on NHC in vitro

2020 ◽  
Author(s):  
Lara Bittmann
Keyword(s):  
World Health Organization ◽  
Clinical Picture ◽  
Treatment Options ◽  
World Health ◽  
Wuhan City ◽  
The World ◽  
Novel Coronavirus ◽  
Health Organization

On December 31, 2019, WHO was informed of cases of pneumonia of unknown cause in Wuhan City, China. A novel coronavirus was identified as the cause by Chinese authorities on January 7, 2020 and was provisionally named "2019-nCoV". This new Coronavirus causes a clinical picture which has received now the name COVID-19. The virus has spread subsequently worldwide and was explained on the 11th of March, 2020 by the World Health Organization to the pandemic.

The Pandemic of Novel Coronavirus Disease 2019 (COVID-19): Need for an Immediate Action (Preprint)

2020 ◽  
Author(s):  
Mujib Ullah
Keyword(s):  
World Health Organization ◽  
Large Family ◽  
Current Treatment ◽  
World Health ◽  
New Disease ◽  
The World ◽  
Novel Coronavirus ◽  
Health Organization

UNSTRUCTURED Coronaviruses belong to a large family of viruses. Coronavirus also called COVID-19 is a new disease that has not been previously identified in humans. The World Health Organization has announced that COVID-19 is a pandemic. Currently there is no specific vaccine or treatment for COVID-19. Current treatment for COVID-19 is only supportive (treating the symptoms). There are no antiviral or vaccine options at this time. Therefore, it is time to bring collective efforts to treat or prevent a rapidly evolving pandemic of COVID-19.

scholarly journals The 2016 Vaccine Development Pipeline: A special issue from the World Health Organization Product Development for Vaccine Advisory Committee (PDVAC)

Vaccine ◽  
2016 ◽  
Vol 34 (26) ◽  
pp. 2863-2864 ◽  
Author(s):  
Birgitte K. Giersing ◽  
Kayvon Modjarrad ◽  
David C. Kaslow ◽  
Jean-Marie Okwo-Bele ◽  
Vasee S. Moorthy
Keyword(s):  
Product Development ◽  
World Health Organization ◽  
Advisory Committee ◽  
Vaccine Development ◽  
World Health ◽  
Special Issue ◽  
The World ◽  
Development Pipeline ◽  
Health Organization

scholarly journals A review of post infectious pulmonary fibrosis in the era of COVID-19 and potential treatment options

2021 ◽  
Vol 9 (40) ◽  
pp. 37-46
Author(s):  
Medha Ghose ◽  
Maehali Patel
Keyword(s):  
Risk Factors ◽  
Pulmonary Fibrosis ◽  
Treatment Options ◽  
World Health ◽  
Potential Treatment ◽  
Pulmonary Injury ◽  
The World ◽  
Health Organization ◽  
Post Infectious

On March 11, 2020, the World Health Organization (WHO) released a statement characterizing COVID-19 as a pandemic that has, as of October 2020, caused almost 36 million confirmed global cases and over 1 million deaths. One of the long-term complications suggested by researchers is fibrosis. It has been hypothesized that the combination of ongoing pulmonary injury caused by COVID-19 and the inability to promptly repair damage results in interstitial matrix widening and eventual compression and destruction of alveoli and capillaries. Here we focus on pathogenesis, risk factors, different infectious causes of fibrosis along with COVID-19, and potential treatment options that might reduce its effects. Key words: COVID-19, pulmonary fibrosis, mechanism, treatment

scholarly journals INFERTILITY MANAGEMENT THROUGH AYURVEDA SHODHANA KARMA- A CASE REPORT

2019 ◽  
pp. 171-173
Author(s):  
Pooja .S. Dhuria ◽  
Prathima
Keyword(s):  
Treatment Options ◽  
Female Infertility ◽  
Reproductive Age ◽  
World Health ◽  
Clinical Feature ◽  
Traditional System ◽  
The World ◽  
One Year ◽  
Health Organization ◽  
Consecutive Cycle

Purpose: The World Health Organization (WHO) estimate that 60 to 80 million couples worldwide currently suffer from infertility. The female infertility has becomes major issue in current scenario due to the increasing number of incidences day by day. In India alone many couples suffers from infertility. The treatment options of female infertility also improving and traditional system of medicine such as Ayurveda describes female infertility broadly with its treatment protocol.Infertility affects women of reproductive age group all over the world. The infertility can be primary or secondary. Panchakarma can treat infertility successfully using various methods along with Ayurvedic formulations. Methodology: A Female Patient of 26 year came to OPD presenting with the complaints of inability to Conceive. Patient was complaining of delayed and heavy menstrual Periods as a clinical feature of PCOD which was diagnosed in USG report Patient was treated with Panchakarma and Ayurvedic Oral medicine. Vamana karma was done and in next Consecutive Cycle Patient got conceived. Result: In next Consecutive Cycle Patient got conceived and she is under regular Antenatal check up. Conclusion: Infertility is defined as a failure to conceive within one year or more years of regular unprotected coitus. PCOD occurs due to an imbalance caused by any of the three Doshas which affect the fertility of the female. These causes increase of Kapha and Vata Dosha and cause the formation of the multiple cysts in ovaries leading to anovulatory periods followed by obesity, hirustitsm. Vamana Karma helps in Strotoshudhi and help in the kapha disorders. Pushpadhanwa rasa act on the Manashanthi and Garbhakrut. Ashwagandha Ksheerpaka acts as Garbhasthapaka and Rasayana. The present study reveals the effective management of infertility associated with PCOD was managed by Shodana and Garbhasthapaka oushadhi KEYWORDS: PCOS, Artava Dusti ,Sthoulya, Infertility

scholarly journals Development of a public geographical information system-based website to follow the impact of control activities of soil-transmitted helminths in endemic countries

2021 ◽  
Vol 16 (2) ◽  
Author(s):  
Maria Paola Maurelli ◽  
Paola Pepe ◽  
Antonio Montresor ◽  
Denise Mupfasoni ◽  
Martina Nocerino ◽  
...  
Keyword(s):  
Neglected Tropical Diseases ◽  
Mortality Rates ◽  
Geographical Information ◽  
World Health ◽  
High Morbidity ◽  
Preventive Chemotherapy ◽  
The World ◽  
Pharmaceutical Industries ◽  
Health Organization ◽  
The Impact

Soil-transmitted helminth (STH) infections are among the most common neglected tropical diseases worldwide causing high morbidity and mortality rates in endemic areas. Preventive chemotherapy (PC) programmes and health education are recommended by the World Health Organization (WHO) to reduce the impact of STH in endemic countries. Following our role as WHO collaborating centre (WHO CC ITA-116), we have developed a WebGIS and a dataset to support PC programmes to monitor the impact of STH control. This vHealth presentation shows the potentiality of these tools in improving communication among WHO’s regional and country offices, Ministries of Health, pharmaceutical industries and other partners.

scholarly journals COVID-19: general overview, pharmacological options and ventilatory support strategies

2020 ◽  
Vol 15 ◽  
Author(s):  
Francesco Menzella ◽  
Andrea Matucci ◽  
Alessandra Vultaggio ◽  
Chiara Barbieri ◽  
Mirella Biava ◽  
...  
Keyword(s):  
Randomized Clinical Trials ◽  
Treatment Options ◽  
Pulmonary Inflammation ◽  
Invasive Mechanical Ventilation ◽  
Ventilatory Support ◽  
Current Treatment ◽  
World Health ◽  
Effective Vaccine ◽  
High Flow Oxygen ◽  
The World

The novel coronavirus called “Severe Acute Respiratory Syndrome Coronavirus 2” (SARS-CoV-2) caused an outbreak in December 2019, starting from the Chinese city of Wuhan, in the Hubei province, and rapidly spreading to the rest of the world. Consequently, the World Health Organization (WHO) declared that the coronavirus disease of 2019 (COVID-19) can be characterized as a pandemic. During COVID-19 several immunological alterations have been observed: in plasma of severe patients, inflammatory cytokines are at a much higher concentration (“cytokine storm”). These aspects are associated with pulmonary inflammation and parenchymal infiltrates with an extensive lung tissue damage in COVID-19 patients. To date, clinical evidence and guidelines based on reliable data and randomized clinical trials (RCTs) for the treatment of COVID-19 are lacking. In the absence of definitive management protocols, many treatments are currently being evaluated worldwide. Some of these options were soon abandoned due to ineffectiveness, while others showed promising results. As for ventilatory strategies, at the moment there are still no consistent data published about the different approaches and how they may influence disease progression. What will probably represent the real solution to this pandemic is the identification of a safe and effective vaccine, for which enormous efforts and investments are being put in place. This review will summarize the state-of-the-art of COVID-19 current treatment options and those potentially available in the future, as well as high flow oxygen therapy and non-invasive mechanical ventilation approaches.

scholarly journals ADME and Pharmacokinetic Properties of Remdesivir: Its Drug Interaction Potential

2021 ◽  
Vol 14 (7) ◽  
pp. 655
Author(s):  
Subrata Deb ◽  
Anthony Allen Reeves ◽  
Robert Hopefl ◽  
Rebecca Bejusca
Keyword(s):  
Drug Interaction ◽  
Ebola Virus ◽  
Treatment Guidelines ◽  
Treatment Options ◽  
World Health ◽  
Nucleoside Triphosphate ◽  
Treatment Regimens ◽  
Global Pandemic ◽  
The World ◽  
Health Organization

On 11 March 2020, the World Health Organization (WHO) classified the Coronavirus Disease 2019 (COVID-19) as a global pandemic, which tested healthcare systems, administrations, and treatment ingenuity across the world. COVID-19 is caused by the novel beta coronavirus Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Since the inception of the pandemic, treatment options have been either limited or ineffective. Remdesivir, a drug originally designed to be used for Ebola virus, has antiviral activity against SARS-CoV-2 and has been included in the COVID-19 treatment regimens. Remdesivir is an adenosine nucleotide analog prodrug that is metabolically activated to a nucleoside triphosphate metabolite (GS-443902). The active nucleoside triphosphate metabolite is incorporated into the SARS-CoV-2 RNA viral chains, preventing its replication. The lack of reported drug development and characterization studies with remdesivir in public domain has created a void where information on the absorption, distribution, metabolism, elimination (ADME) properties, pharmacokinetics (PK), or drug-drug interaction (DDI) is limited. By understanding these properties, clinicians can prevent subtherapeutic and supratherapeutic levels of remdesivir and thus avoid further complications in COVID-19 patients. Remdesivir is metabolized by both cytochrome P450 (CYP) and non-CYP enzymes such as carboxylesterases. In this narrative review, we have evaluated the currently available ADME, PK, and DDI information about remdesivir and have discussed the potential of DDIs between remdesivir and different COVID-19 drug regimens and agents used for comorbidities. Considering the nascent status of remdesivir in the therapeutic domain, extensive future work is needed to formulate safer COVID-19 treatment guidelines involving this medication.

Sign in / Sign up

Export Citation Format

Share Document